Entera Bio Ltd

5DT

Company Profile

  • Business description

    Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

  • Contact

    Minrav Building - Fifth Floor
    Kiryat Hadassah
    Jerusalem9112002
    ISR

    T: +972 25327151

    E: [email protected]

    https://www.enterabio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    22

Stocks News & Analysis

stocks

Nvidia earnings: Another stellar quarter with no signs of a slowdown

Nvidia remains at the heart of the AI ecosystem.
stocks

Chart of the Week: Software selloff creates opportunity for these two stocks

Can AI disrupt the software business model?
stocks

Market is misinterpreting AI impact on cheap ASX share

Unwarranted sell-off with shares down by half in three months.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,408.7027.40-0.29%
CAC 408,620.9361.860.72%
DAX 4025,289.02113.080.45%
Dow JONES (US)49,499.2017.050.03%
FTSE 10010,846.7040.290.37%
HKSE26,381.02384.70-1.44%
NASDAQ22,878.38273.69-1.18%
Nikkei 22558,753.39170.270.29%
NZX 50 Index13,651.5719.14-0.14%
S&P 5006,908.8637.27-0.54%
S&P/ASX 2009,175.3027.60-0.30%
SSE Composite Index4,146.630.60-0.01%

Market Movers